|
original article |
Date |
Title |
Authors Max. 6 Authors |
1 |
[GO] |
2024―Apr―15 |
Research Trends in Proteomic Studies Using Serum from COVID-19
Patients: A Bibliometric Analysis |
Érika Alves da Fonsêca Amorim, Roberval Nascimento Moraes Neto, Ana Viviam Souza, Camila Guerra Martinez, Adrielle Zagmignan, Luís Cláudio Nascimento da Silva |
2 |
[GO] |
2024―Apr―09 |
Discovery of Novel Natural Inhibitors Against SARS-CoV-2 Main Protease: A Rational Approach to Antiviral Therapeutics |
Muhammad Waqas, Saeed Ullah, Sobia Ahsan Halim, Inam Ullah, Afnan Jan, Asaad Khalid, Amjad Ali, Ajmal Khan, Ahmed Al-Harrasi |
3 |
[GO] |
2024―Mar―26 |
Fragment-based Drug Discovery Strategy and its Application to the
Design of SARS-CoV-2 Main Protease Inhibitor |
Yu Jiang, Yingnan Wu, Jing Wang, Yuheng Ma, Hui Yu, Zhanli Wang |
4 |
[GO] |
2024―Feb―04 |
Role of Ferroptosis in the Progression of COVID-19 and the Development of Long COVID |
Wen Zhao, Siyuan Wang, Yuxin Han, Hongkun Zhang, Jiacen Cao, Shasha Dong, Dongdong Li, Miao Lei, Chuanmiao Liu, Yu Gao |
5 |
[GO] |
2024―Jan―29 |
Time Course of Biochemical and Metabolic Parameters During and
After COVID-19 |
Zohreh-al-sadat Ghoreshi, Mojtaba Abbasi-jorjandi, Gholamreza Asadikaram, Mohsen Sharif-zak, Mohammad Khaksari Haddad, Ali Afgar, Nasir Arefinia, Shahriar Dabiri, Clifford Rosen |
6 |
[GO] |
2024―Jan―22 |
Atorvastatin Effect on COVID-19 Outcomes: A Propensity Score
Matched Study on Hospitalized Patients |
Mohamad Amin Pourhoseingholi, Omid Yazdani, Mehdi Azizmohammad Looha, Seyed Amir Ahmad Safavi-Naini, Romina Esbati, Saba Ilkhani, Nazanin Taraghikhah, Hamidreza Hatamabadi, Amir Sadeghi, Kamran Heidari, Negarsadat Namazi, Naghmeh Asadimanesh, Saba Hatari, Shabnam Shahrokh, Ali Solhpour, Tannaz Jamialahmadi, Raul D. Santos, Amirhossein Sahebkar |
7 |
[GO] |
2024―Jan―22 |
Genetic and Epigenetic Determinants of COVID-19 Susceptibility: A
Systematic Review |
Amin Gasmi, Laura Kassym, Alain Menzel, Wajiha Anzar, Maryam Dadar, Yuliya Semenova, Mehreen Arshad, Tetyana Bihunyak, Nagwa Abdel Meguid, Massimiliano Peana, Zhanagul Bekbergenova, Geir Bjørklund |
8 |
[GO] |
2024―Jan―21 |
Natural and Synthetic Coumarins as Potential Drug Candidates Against SARS-CoV-2/CoViD-19 |
Iara da Silva Santos, Letícia Oliveira Magalhães, Roberta Katlen Fusco Marra, Camilo Henrique da Silva Lima, Lidilhone Hamerski, Magaly Girão Albuquerque, Bárbara Vasconcellos da Silva |
9 |
[GO] |
2023―Dec―15 |
Promises and Pitfalls of Calcineurin Inhibitors in COVID-19: A Systematic Review and Meta-analysis of Controlled Trials |
Behrooz Heydari, Adeleh Sahebnasagh, Mohammad Ali Omrani, Saeed Azimi, Mohammad Hossein Dehghani, Amin Salehi-Abargouei, Farnoosh Farman, Fatemeh Saghafi |
10 |
[GO] |
2023―Nov―29 |
Structure and Function of the SARS-CoV-2 6-HB Fusion Core and Peptide-Based Fusion Inhibitors: A Review |
Guodong Liang, Yue Li, Ruijuan Li, Yuheng Ma, Heiya Na |
11 |
[GO] |
2023―Nov―28 |
SARS-CoV-2 Main Protease Inhibitors from Natural Product Repository as Therapeutic Candidates for the Treatment of Coronaviridae
Infections |
Mohammad A. Khanfar, Mohammad I. Saleh |
12 |
[GO] |
2023―Sep―19 |
How does the Immunological System Change during the SARS-COV-2 Attack? A Clue for the New Immunotherapy Discovery |
Mohammad Mahdi Hajihasani, Najmeh Kaffash Farkhad, Ali Mahmoudi, Amirhossein Sahebkar |
13 |
[GO] |
2023―Sep―11 |
Identifying luteolin as a potential drug for treating lung adenocarcinoma with COVID-19 affection based on integration analysis of pharmacology and transcriptome |
Ping Peng, Na Li, Ni Zhang, Xiangning Fu, Shu Peng, Yujie Zhao, Bo Ai |
14 |
[GO] |
2023―Sep―11 |
Antiviral Compounds to Address Influenza Pandemics: An Update from 2016-2022 |
Roberto Romeo, Laura Legnani, Maria Assunta Chiacchio, Salvatore V. Giofrè, Daniela Iannazzo |
15 |
[GO] |
2023―Jul―30 |
The Role of Endothelial Related Circulating Biomarkers in COVID-19. A Systematic Review and Meta-analysis |
|
16 |
[GO] |
2023―Jul―30 |
Anti-Coronavirus Vaccines: Past Investigations on SARS-CoV-1 and MERS-CoV, the Approved Vaccines from BioNTech/Pfizer, Moderna, Oxford/AstraZeneca and others under Development Against SARS-CoV-2 Infection |
|
17 |
[GO] |
2023―Jul―30 |
The Impact of Vaccination Worldwide on SARS-CoV-2 Infection: A Review on Vaccine Mechanisms, Results of Clinical Trials, Vaccinal Coverage and Interactions with Novel Variants |
|
18 |
[GO] |
2023―Jul―30 |
Cordycepin as a Promising Inhibitor of SARS-CoV-2 RNA dependent RNA polymerase (RdRp) |
|
19 |
[GO] |
2023―Jul―18 |
Potential drugs in COVID-19 management |
Geir Bjørklund, Amin Gasmi, Sadaf Noor, Alain Menzel, Nataliia Khanyk, Yuliya Semenova, Roman Lysiuk, Nataliya Beley, Lidiia Bolibrukh, Asma Gasmi Benahmed, Olha Storchylo |
20 |
[GO] |
2023―Jul―07 |
Fluvastatin: a choice for COVID-19 associated mucormycosis management |
Amirhossein Sahebkar, Alireza Tavakkoli, Thomas P. Johnston |
21 |
[GO] |
2023―Jun―21 |
Severity of COVID-19 in pregnant women: a review on the potential role of regulatory T cells |
Elham Abdollahi, Amirhossein Sahebkar, Nafiseh Saghafi, Mahmoud Mahmoudi, Amir Abbas Momtazi-Borojeni, Sara Mirzaeian, Fataneh Tavasolian, Thozhukat Sathyapalan |
22 |
[GO] |
2023―May―22 |
Discovery of Novel Cysteine Protease Inhibitors for the Treatment of Coronavirus (COVID-19) |
Surya K. De |
23 |
[GO] |
2023―May―16 |
Long COVID-19 syndrome and sudden cardiac death: the phantom menace |
Michael Spartalis, David Zweiker, Eleftherios Spartalis, Dimitrios C. Iliopoulos, Gerasimos Siasos |
24 |
[GO] |
2023―May―16 |
The impact of lncRNA-GAS5/miRNA-200/ACE2 molecular pathway on the severity of COVID-19 |
Amr M. Abdelhamid, Ghada Ayeldeen, Olfat G. Shaker, Eman Amer, Mai A. Zaafan, Mohamed R. Herzalla, Mofida A. Keshk |
25 |
[GO] |
2023―May―05 |
Recent Discovery of Peptidomimetics for the Treatment of Coronavirus (COVID-19), Human coronavirus, and Enteroviruses |
Surya K. De |
26 |
[GO] |
2023―May―04 |
Hydrogen sulfide: physiological roles and therapeutic implications against COVID-19 |
Amirhossein Sahebkar, Sajad Abolfazli, Nima Ebrahimi, Eftekhar Morabi, Mohammad Amin Asgari Yazdi, Gokhan Zengin, Thozhukat Sathyapalan, Tannaz Jamialahmadi |
27 |
[GO] |
2023―Apr―09 |
Perspectives and Prospects on the application of DNA Aptamer in SARS-CoV-2 |
Xiaoxiao Hu, Yunyi Liu, Bei Hu, Xiaming Pei, Juan Li |
28 |
[GO] |
2023―Mar―31 |
SARS-CoV-2 Infection, Inflammation, Immunonutrition, and Pathogenesis of COVID-19 |
Ligen Yu, Mohd Khanapi Abd Ghani, Alessio Aghemo, Debmalya Barh, Matteo Bassetti, Fausto Catena, Gaetano Gallo, Ali Gholamrezanezhad, Mohammad Amjad Kamal, Amos Lal, Kamal Kant Sahu, Shailendra K Saxena, Ugo Elmore, Farid Rahimi, Chiara Robba, Yuanlin Song, Zhengyuan Xia, Boxuan Yu |
29 |
[GO] |
2023―Mar―31 |
Traditional Chinese Medicine as the preventive and therapeutic remedy for COVID-19 |
Geir Bjørklund, Amin Gasmi, Torsak Tippairote, Pavan Kumar Mujawdiya, Alain Menzel, Roman Lysiuk, Mariia Shanaida, Larysa Lenchyk, Massimiliano Peana |
30 |
[GO] |
2023―Feb―24 |
Sleep, dietary melatonin supplementation, and COVID-19 |
Geir Bjørklund, Amin Gasmi, Yuliya Semenova, Sadaf Noor, Asma Gasmi Benahmed |
31 |
[GO] |
2023―Feb―23 |
Percutaneous Coronary Intervention Associated with a Higher Risk of Hypoxemia and COVID-19 Severity |
Amirhossein Sahebkar, Sepideh Karkon Shayan, Elham Nasrollahi, Yaser Bahramvand, Mahdi Zarei, Ahmadreza Atarodi, Yeganeh Farsi, Mitra Tavakolizadeh, Milad Shirvaliloo, Mitra Abbasifard, Tannaz Jamialahmadi, Maciej Banach |
32 |
[GO] |
2023―Feb―06 |
Is BMI Associated with Covid-19 Severity? A Retrospective Observational Study |
Marcello Candelli, Giulia Pignataro, Angela Saviano, Veronica Ojetti, Maurizio Gabrielli, Andrea Piccioni, Antonio Gullì, Massimo Antonelli, Antonio Gasbarrini, Francesco Franceschi |
33 |
[GO] |
2022―Dec―07 |
The Role of Interleukin-6 in the Pathogenesis, Prognosis and Treatment of Severe COVID-19 |
Ilias Giannakodimos |
34 |
[GO] |
2022―Dec―07 |
Current Scenario and Future Prospect in the Management of COVID-19 |
Pobitra Borah |
35 |
[GO] |
2022―Dec―07 |
The Role of Endothelial Related Circulating Biomarkers in COVID-19. A Systematic Review and Meta-analysis |
Stamatios Lampsas |
36 |
[GO] |
2022―Dec―07 |
The Chronicle of COVID-19 and Possible Strategies to Curb the Pandemic |
Rajesh Kumar |
37 |
[GO] |
2022―Dec―07 |
Targeting COVID-19 in Parkinsons Patients: Drugs Repurposed |
Firoz Anwar |
38 |
[GO] |
2022―Dec―07 |
COVID-19 Vaccine Race: Analysis of Age-Dependent Immune Responses against SARS-CoV-2 Indicates that more than Just One Strategy May Be Needed |
Mercedes Jimenez |
39 |
[GO] |
2022―Dec―07 |
Anti-Coronavirus Vaccines: Past Investigations on SARS-CoV-1 and MERS-CoV, the Approved Vaccines from BioNTech/Pfizer, Moderna, Oxford/AstraZeneca and others under Development Against SARSCoV- 2 Infection |
Michele Costanzo |
40 |
[GO] |
2022―Dec―07 |
Cordycepin as a Promising Inhibitor of SARS-CoV-2 RNA Dependent RNA Polymerase (RdRp) |
Shabana Bibi |
41 |
[GO] |
2022―Oct―18 |
Targeting COVID-19 in Parkinson’s Patients: Drugs Repurposed |
Firoz Anwar |
42 |
[GO] |
2022―Oct―18 |
SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus |
Michele Costanzo |
43 |
[GO] |
2022―Oct―18 |
In Vitro Data of Current Therapies for SARS-CoV-2 |
Ioanna Anastasiou |
44 |
[GO] |
2022―Oct―05 |
COVID-19 and Alzheimer's Disease:
Neuroinflammation, Oxidative Stress, Ferroptosis, and Mechanisms Involved |
Alicia B. Pomilio, Arturo A. Vitale, Alberto J. Lazarowski |
45 |
[GO] |
2022―Oct―05 |
Looking for SARS-CoV-2 therapeutics through computational approaches |
Marilisa Leone, Marian Vincenzi, Flavia Anna Mercurio |
46 |
[GO] |
2022―Sep―23 |
Novel Proline derivatives for Treating COVID-19 |
Surya K. De |
47 |
[GO] |
2022―Sep―06 |
Putative Therapeutic Impact of Inflammasome Inhibitors against COVID-19-Induced ARDS |
Seyed Mohammad Nabavi, Aysa Rezabakhsh, Seyed Fazel Nabavi, Adeleh Sahebnasagh, Ahad Shahbazi, Mojde Rahmani, Saeid Azimi, Malihe Khayat kashani, Solomon Habtemariam, Mohadese Badiee, Javad Hashemi, Fatemeh Saghafi, Kiumarth Amini, Mina Azimi |
48 |
[GO] |
2022―Aug―30 |
Cannabinoids receptors in Covid-19: Perpetrators and victims |
Athanasios Alexiou, Gaber El-Saber Batiha, Hayder M. Al-kuraishy, Ali I. Al-Gareeb |
49 |
[GO] |
2022―Jul―28 |
SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus |
|
50 |
[GO] |
2022―Jul―04 |
Imaging markers of neurologic damage in COVID-19: a systematic review |
Sara Tavares Araújo, Clara Tavares Araújo, Rafael Silva e Castro, Lara Machado de Oliveira Brügger, Nathália Gualberto Souza e Silva, Debora Marques de Miranda, Ana Cristina Simões e Silva |
51 |
[GO] |
2022―Jun―28 |
Review on In silico Methods, High-throughput Screening Techniques, and Cell Culture Based In Vitro Assays for SARS-CoV-2.. |
Yuksel Cetin, Seyma Aydinlik, Aysen Gungor, Tugce Kan, Timucin Avsar, Serdar Durdagi |
52 |
[GO] |
2022―May―07 |
Chronic systemic low-grade inflammation and modern lifestyle: the dark role of gut microbiota on related diseases with a focus on pandemic COVID-19 |
Tiziana Mundula, Edda Russo, Lavinia Curini, Francesco Giudici, Andrea Piccioni, Francesco Franceschi, Amedeo Amedei |
53 |
[GO] |
2022―Mar―02 |
COVID-19 Effects on Geriatric Populationand Failures of Aminoquinoline Therapy: Compilation of Studies from EU, USA, and China; Safety and Efficacy of Vaccinesin the Prevention & Treatment of COVID-19 |
Narasimha M. Beeraka, SubbaRao V Tulimilli, M V Greeshma, Siva Dallavalasa, Yaowen Zhang, Wenjing Xiao, Ruitai Fan, Di Zhao, Anjali Devi S. Bettadapura, Suma M. Natraj, SubbaRao V Madhunapantula, Junqi Liu |
54 |
[GO] |
2022―Feb―16 |
Perspectives and Prospects on mRNA Vaccine
Development for COVID-19 |
Lihui Jin, Zhenyuan Han, Pengjun Zhao, Kun Sun |
55 |
[GO] |
2022―Feb―14 |
Aptamer-based Emerging Tools for Viral Biomarker Detection: A focus on SARS-CoV-2 |
Prabir Kumar Kulabhusan, Parsa Pishva, Eda Çapkın, Prajakta Tambe, Meral Yüce |
56 |
[GO] |
2021―Oct―27 |
The Role of Endothelial Related Circulating Biomarkers in COVID-19. A Systematic Review and Meta-analysis |
Stamatios Lampsas, Paraskevas Tsaplaris, Panteleimon Pantelidis, Evangelos Oikonomou, Georgios Marinos, Georgios Charalambous, Nektarios Souvaliotis, Vasiliki-Chara Mystakidi, Athina Goliopoulou, Efstratios Katsianos, Gerasimos Siasos, Michael-Andrew Vavuranakis, Costas Tsioufis, Manolis Vavuranakis, Dimitrios Tousoulis |
57 |
[GO] |
2021―Sep―02 |
The impact of Vaccination worldwide on SARS-CoV-2 infection: A Review on Vaccine Mechanisms, Results of Clinical Trials, Vaccinal Coverage and Interactions with Novel Variants |
Douglas Henrique Pereira Damasceno, Arthur Aguiar Amaral, Cecília Andrade Silva, Ana Cristina Simões e Silva |
58 |
[GO] |
2021―Aug―23 |
Cordycepin as a Promising Inhibitor of SARS-CoV-2 RNA dependent RNA polymerase (RdRp) |
Shabana Bibi, Mohammad Mehedi Hasan, Yuan-Bing Wang, Stavros P. Papadakos, Hong Yu |
59 |
[GO] |
2021―Jul―27 |
Natural Products with tandem Anti-inflammatory, Immunomodulatory and Anti-SARS-CoV/2 effects: A Drug Discovery Perspective against SARS-CoV-2 |
Luana N. O. Leal da Cunha, Tiago Tizziani, Gabriella B. Souza, Monalisa A. Moreira, José S. S. Neto, Carlos V. D. dos Santos, Maryelle G. de Carvalho, Eduardo M. Dalmarco, Leonardo B. Turqueti, Marcus Tullius Scotti, Luciana Scotti, Francisco F. de Assis, Antonio Braga, Louis Pergaud Sandjo |
60 |
[GO] |
2021―Jun―24 |
Interfering Reactive Cysteine Proteome in Covid-19 Disease |
Marcos Martinez-Banaclocha |
61 |
[GO] |
2021―Jun―15 |
Natural Substances in the Fight of SARS-CoV-2: A Critical Evaluation Resulting from the Cross-Fertilization of Molecular Modeling Data with the Pharmacological Aspects |
Davide Gentile, Vincenzo Patamia, Virginia Fuochi, Pio M. Furneri, Antonio Rescifina |
62 |
[GO] |
2021―May―27 |
COVID-19: The significance of platelets, mitochondria, vitamin D, serotonin and the gut microbiota |
István Bókkon, Gábor Kapócs, András Vucskits, Attila Erdöfi-Szabó, Jan Vagedes, Felix Scholkman, Henrik Szőke |
63 |
[GO] |
2021―May―27 |
Interfering with Host Proteases in SARS-CoV-2 Entry as a Promising Therapeutic Strategy |
Patrick Müller, Hannah Maus, Stefan Josef Hammerschmidt, Philip Knaff, Volker Mailänder, Tanja Schirmeister, Christian Kersten |
64 |
[GO] |
2021―May―22 |
Anti-Coronavirus Vaccines: Past Investigations on SARS-CoV-1 and MERS-CoV, the Approved Vaccines from BioNTech/Pfizer, Moderna, Oxford/AstraZeneca and others under Development Against SARS-CoV-2 Infection |
Michele Costanzo, Maria Anna Rachele De Giglio, Giovanni N. Roviello |
65 |
[GO] |
2021―May―10 |
SARS-CoV-2 Induced Neurological Manifestations Entangles Cytokine Storm That Implicates For Therapeutic Strategies |
Zhao-Zhong Chong, Nizar Souayah |
66 |
[GO] |
2021―May―05 |
Severe Acute Respiratory Syndrome Coronavirus -2 (SARS-CoV-2): A Review on Pathophysiology, Diagnosis and Investigational Therapeutics |
Rahul Sharma, Dharmendra Khokhar, Bhanushree Gupta, Purnendu Saxena, Kallol Kumar Ghosh, Arvind Kumar Geda, Kamil Kuca |
67 |
[GO] |
2021―Apr―06 |
The Main Receptors Involved with COVID-19: a Systematic Review and Meta-analysis |
Alice Barros Câmara, Igor Augusto Brandão |
68 |
[GO] |
2021―Mar―30 |
Protein-ligand Docking Simulations with AutoDock4 Focused on the Main Protease of SARS-CoV-2 |
Walter Filgueira de Azevedo Junior, Gabriela Bitencourt-Ferreira, Joana Retzke Godoy, Hilda Mayela Aran Adriano, Wallyson André dos Santos Bezerra, Alexandra Martins dos Santos Soares |
69 |
[GO] |
2021―Feb―19 |
Advances of Inorganic Materials in the Detection and Therapeutic Uses Against Coronaviruses |
Sathish Veerasamy, Manivannan Chandrakumar, Malathi Balasubramaniyan, Ramesh Kumar Arumugam, Thanasekaran Pounraj |
70 |
[GO] |
2021―Feb―15 |
Renin Angiotensin System in Central Nervous System diseases and its interaction with COVID-19 |
Katharina Lanza, Raphael Dias, Rafaela dos Santos Oliveira, Luís Belotto, Aline Silva Miranda, Ana Cristina Simões e Silva |
71 |
[GO] |
2021―Feb―10 |
Nucleoside Inhibitors of Coronaviruses |
Anastasia A. Zenchenko, Mikhail S. Drenichev, Sergey N. Mikhailov |
72 |
[GO] |
2021―Jan―26 |
Natural Products as Potential Agents Against SARS-CoV and SARS-CoV-2 |
Joanda Paolla Raimundo e Silva, Chonny Alexander Herrera Acevedo, Thalisson Amorim de Souza, Renata Priscila Barros de Menezes, Zoe L. Sessions, Lucas Silva Abreu, Samuel Paulo Cibulski, Luciana Scotti, Marcelo Sobral da Silva, Eugene N. Muratov, Marcus Tullius Scotti, Josean Fechine Tavares |
73 |
[GO] |
2021―Jan―14 |
Deep learning in the quest for compound nomination for fighting COVID-19 |
Maria Mernea, Eliza. C. Martin, Andrei-José Petrescu, Speranta Avram |
74 |
[GO] |
2021―Jan―08 |
Machine Intelligence Techniques for the Identification and Diagnosis of COVID-19 |
Sumera Zaib, Nehal Rana, Areeba Noor, Imtiaz Khan |
75 |
[GO] |
2020―Dec―10 |
The role of Interleukin-6 in the pathogenesis, prognosis and treatment of severe COVID-19 |
Ilias Giannakodimos, Georgia-Vasiliki Gkountana, Dimosthenis Lykouras, Kiriakos Karkoulias, Sotiris Tsakas |
76 |
[GO] |
2020―Oct―28 |
COVID-19 vaccine race: analysis of age-dependent immune responses against SARS-CoV-2 indicates that more than just one strategy may be needed. |
Nuria E. Campillo, Mercedes Jimenez, Matilde Canelles |
77 |
[GO] |
2020―Oct―28 |
COVID-19: innovative antiviral drugs required for long-term prevention and control of coronavirus diseases |
Norman A. Ratcliffe, Helena C. Castro, Izabel C. Paixão, Cicero B. Mello |
78 |
[GO] |
2020―Oct―28 |
Recent Advances towards Drug Design Targeting the Protease of 2019 novel coronavirus (2019-nCoV) |
Sehrish Bano, Abdul Hameed, Mariya Al-Rashida, Shafia Iftikhar, Jamshed Iqbal |
79 |
[GO] |
2020―Oct―27 |
Evidence and the main adverse effects regarding drug therapies in the war against COVID-19 |
Mauricio Mora-Ramírez, Paulina Melgoza-Hernández, Sebastian Eduardo Toledo-Ramírez, Juan Manuel Mejía Aranguré |
80 |
[GO] |
2020―Oct―06 |
COVID-19 related coagulopathy: what is known up to now |
Ana Luísa Batista Pena, Rafael Arantes Oliveira, Renata Gomes Severo, Ana Cristina Simões e Silva |
81 |
[GO] |
2020―Sep―09 |
Current scenario and future prospect in the management of COVID-19 |
Pobitra Borah, Pran Kishore Deb, Satyendra Deka, Katharigatta N. Venugopala, Vinayak Singh, Raghu Prasad Mailavaram, Kiran Kalia, Rakesh Kumar Tekade |
82 |
[GO] |
2020―Sep―05 |
Targeting COVID-19 in Parkinson’s patients: Drugs repurposed. |
Firoz Anwar, Salma Naqvi, Fahad A. Al-Abbasi, Nauroz Neelofar, Vikas Kumar, Ankit Sahoo, Mohammad Amjad Kamal |
83 |
[GO] |
2020―Sep―03 |
Renin-angiotensin system (RAS) and immune system profile in specific subgroups with COVID-19 |
Ludimila de Barcelos Ubaldo Martins, Luiz Gustavo Pessoa Pires Jabour, Cristina Cerqueira Vieira, Lucas Crepaldi Carvalho Nery, Raphael Figuiredo Dias, Ana Cristina Simões e Silva |
84 |
[GO] |
2020―Jul―22 |
Current Trends and Future Approaches in Small-Molecule Therapeutics for COVID-19 |
Mark Laws, Yasmin M. Surani, Md. Mahbub Hasan, Yiyuan Chen, Peiqin Jin, Taha AlAdhami, Madiha Chowdhury, Aqeel Imran, Ioannis Psaltis, Shirin Jamshidi, Kazi S. Nahar, Khondaker Miraz Rahman |
85 |
[GO] |
2020―Jul―11 |
Current Paradigms in COVID-19 Research: Proposed Treatment Strategies, Recent Trends and Future Directions |
Anil K. Sharma, Varruchi Sharma, Arun Sharma, Suresh Pallikkuth |
86 |
[GO] |
2020―Jul―02 |
The chronicle of COVID-19: possible strategies to curb the pandemic |
Rajesh Kumar, Seetha Harilal, Abdullah G. Al-Sehemi, Githa Elizabeth Mathew, Simone Carradori, Bijo Mathew |
87 |
[GO] |
2020―May―13 |
In vitro data of current therapies for SARS-CoV-2 |
Ioanna A. Anastasiou, Ioanna Eleftheriadou, Anastasios Tentolouris, Dimitrios Tsilingiris, Nikolaos Tentolouris |
88 |
[GO] |
2020―Apr―16 |
SARS CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and Other Drugs for the Treatment of the New Coronavirus |
Michele Costanzo, Maria Anna Rachele De Giglio, Giovanni Nicola Roviello |